Permanent congenital hypothyroidism

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:226292
Who is this for?
Show terms as
2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Permanent congenital hypothyroidism (PCH) is a condition in which the thyroid gland fails to produce adequate amounts of thyroid hormones from birth, and this deficiency persists throughout life, requiring lifelong treatment. Unlike transient forms of congenital hypothyroidism that resolve spontaneously, PCH represents an irreversible defect in thyroid hormone production or action. The condition can result from thyroid dysgenesis (absent, ectopic, or hypoplastic thyroid gland), which accounts for approximately 80-85% of cases, or from thyroid dyshormonogenesis (defects in thyroid hormone synthesis), which accounts for most of the remaining cases. Rare forms may also involve defects in thyrotropin (TSH) production or thyroid hormone resistance. Thyroid hormones are critical for normal growth and neurodevelopment, particularly during the first years of life. Without adequate thyroid hormone, affected infants may develop prolonged jaundice, feeding difficulties, constipation, a hoarse cry, hypotonia (decreased muscle tone), a large fontanelle, macroglossia (enlarged tongue), an umbilical hernia, dry skin, and hypothermia. If left untreated, PCH leads to severe and irreversible intellectual disability, growth failure, and delayed skeletal maturation — a condition historically known as cretinism. Newborn screening programs, now implemented in most developed countries, allow early detection of congenital hypothyroidism through measurement of TSH and/or free T4 levels in blood spots collected shortly after birth. Early initiation of levothyroxine (synthetic thyroid hormone) replacement therapy, ideally within the first two weeks of life, is the standard of care and can prevent the neurodevelopmental consequences of the disease. With prompt and adequate treatment, most children with PCH achieve normal cognitive development and growth, though some studies suggest subtle neurocognitive differences may persist. Lifelong monitoring of thyroid function and dose adjustments are essential.

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Permanent congenital hypothyroidism.

View clinical trials →

No actively recruiting trials found for Permanent congenital hypothyroidism at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Permanent congenital hypothyroidism community →

Specialists

2 foundView all specialists →
RM
Rosalind S Brown, MD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Permanent congenital hypothyroidism.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Permanent congenital hypothyroidismForum →

No community posts yet. Be the first to share your experience with Permanent congenital hypothyroidism.

Start the conversation →

Latest news about Permanent congenital hypothyroidism

No recent news articles for Permanent congenital hypothyroidism.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Permanent congenital hypothyroidism

What is Permanent congenital hypothyroidism?

Permanent congenital hypothyroidism (PCH) is a condition in which the thyroid gland fails to produce adequate amounts of thyroid hormones from birth, and this deficiency persists throughout life, requiring lifelong treatment. Unlike transient forms of congenital hypothyroidism that resolve spontaneously, PCH represents an irreversible defect in thyroid hormone production or action. The condition can result from thyroid dysgenesis (absent, ectopic, or hypoplastic thyroid gland), which accounts for approximately 80-85% of cases, or from thyroid dyshormonogenesis (defects in thyroid hormone synth

At what age does Permanent congenital hypothyroidism typically begin?

Typical onset of Permanent congenital hypothyroidism is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Permanent congenital hypothyroidism?

2 specialists and care centers treating Permanent congenital hypothyroidism are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.